☰
✕
Combination of ceftriaxone, sulbactam & EDTA in management of MDR Septicema

Finetriax S (Ceftriaxone + sulbactam)

Combination therapy of ceftriaxone, sulbactam and disodium edetate for the management of multi-drug resistant septicemia

Use of rational combination therapies have been recommended by various studies in the past, for the treatment of multi-drug resistant (MDR) infections. An antibiotic adjuvant entity (AAE) of ceftriaxone, sulbactam and disodium edetate (Elores) was accepted for multi-drug resistant infections in India. The objective of the following retrospective study was to investigate the efficacy and safety of AAE in patients with sepsis due to extended spectrum beta lactamse (ESBL) and metallo-beta lactamase (MBL) producing pathogens.

The study was conducted in patients admitted in intensive care unit (ICU) at tertiary health care site in India, with enrollment from 24 March, 2012 to 7 Aug, 2012. Patients with bacterial septicemia aged between 12-65 years were enrolled for treatment with cephalosporins categories of antibiotics.

The relevant outcomes of the study were:

  • A total number of 18 patients were included in the study and all were assigned to a combination of ceftriaxone, sulbactam and disodium edetate
  • Out of 18 patients, 15 (83.3%) experienced complete clinical cure in terms of relief and no-disease symptoms, while 3 (16.6%) patients showed treatment failure (TF)
  • Likewise 15 (83.3%) patients exhibited complete bacteriological eradication response and 03 (16.6%) were showed TF
  • No serious side effect was observed during the study.

Hence, it was concluded that use of combination of ceftriaxone, sulbactam and disodium edetate (EDTA) is recommended for the management of MDR septicemia associated with ESBL and MBL producing microbes.

"Use of combination of ceftriaxone, sulbactam and disodium edetate (EDTA) is recommended for the management of MDR septicemia associated with ESBL and MBL producing microbes"

Source: Patil UN, Jambulingappa KL. A Combination Strategy of Ceftriaxone, Sulbactam and Disodium Edetate for the Treatment of Multi-Drug Resistant (MDR) Septicaemia: A Retrospective, Observational Study in Indian Tertiary Care Hospital. J Clin Diagn Res. 2015 Nov;9(11):FC29-32.